Section 5: Patient Safety and Quality Assurance

5PSQ-006

DOSING LOW MOLECULAR WEIGHT HEPARINS IN RENAL IMPAIRMENT: A NATIONWIDE SURVEY

5PSQ-004

ANALYSIS OF ADVERSE DRUG REACTIONS OF DISEASE -MODIFYING TREATMENTS IN MULTIPLE SCLEROSIS

5PSQ-156

REASONS FOR SECUKINUMAB TREATMENT DISCONTINUATION

5PSQ-154

Impact of the COVID-19 Pandemic on Antimicrobial Consumption and Antimicrobial Resistance

5PSQ-153

PERSISTENCE AND REASONS FOR DISCONTINUATION OF TREATMENT WITH APREMILAST IN DERMATHOLOGICAL DISEASES

5PSQ-150

Implementation of a Programme for Optimising the Use of Antibiotics (PROA) in the Paediatrics Emergency Care Unit of a third level hospital

5PSQ-149

DURVALUMAB FOR THE TREATMENT OF NONSMALL CELL LUNG CANCER: REAL-WORLD EXPERIENCE

5PSQ-140

PATIENT SAFETY CLIMATE IN A HOSPITAL PHARMACY DEPARTMENT

5PSQ-132

ANALYSIS OF CHEMICAL CONTAMINATION BY HAZARDOUS DRUGS WITH SEMIQUANTITATIVE SYSTEM IN A TERTIARY HOSPITAL

5PSQ-131

PARENTERAL NUTRITION IN ACUTE PANCREATITIS: A REVIEW OF APPROPRIATENESS

5PSQ-128

CLINICAL INTERVENTIONS IN THE AREA OF INPATIENT PRESCRIPTIONS PERFORMED BY HOSPITAL PHARMACY RESIDENT

5PSQ-125​

THE IDENTIFICATION OF HEALTH CONSEQUENCES ASSOCIATED WITH COUNTERFEIT MEDICINE AND ILLEGAL HEALTH PRODUCT APPLICATION USING PHARMACOVIGILANCE DATA

5PSQ-124

THE ROLE OF THE CLINICAL PHARMACIST AVOIDING MEDICATION ERRORS IN A CLINICAL RESEARCH ONCO-HEMATOLOGIC UNIT

5PSQ-122

EXPERIENCE OF BARICITINIB-REMDESIVIR USE IN PATIENTS WITH SARS-COV-2 INFECTION

5PSQ-121

IMPORTANCE OF CONCILIATION IN IMMUNOSUPPRESSANT TREATMENT

Pages